jvgulfo

About Joseph Gulfo

This author has not yet filled in any details.
So far Joseph Gulfo has created 22 blog entries.

Tonic: The FDA Might Pull The Only Treatment for a Rare Form of Muscular Dystrophy by Annamarya Scaccia

Advocates understand that eteplirsen is not a cure-all for Duchenne muscular dystrophy. But it's a start for a condition that has no cure. Joseph Gulfo, a biopharmaceutical expert and outspoken critic of the FDA drug approval process, believes that eteplirsen could be used in conjunction with other drugs, either on the market or on the horizon, similar [...]

Apr 19 2017|Media|

Pinkerton: What Trump’s ‘Great Healthcare Plan for the People’ Might Look Like via Breitbart News

... So here’s one idea, from Dr. Joseph V. Gulfo, MD, of Fairleigh Dickinson University’s Lewis Center for Healthcare Innovation and Technology.  In an interview, Gulfo summed up his idea in two words: wearable technology.  That is, let’s be sure that all our aging heroes in the VA system have access to the sort of ever-present [...]

Apr 3 2017|Media|

STAT News: Trump considers an entrepreneur with sweeping reform plans to run the FDA by Sheila Kaplan

WASHINGTON — Two weeks ago, Dr. Joseph Gulfo ran a panel at the Biotech Showcase in San Francisco titled, “The Trump Administration: What to expect from the FDA.” He left out one key detail: He may end up running the place. Gulfo, who may be the first person in political history to serve as a senior fellow at [...]

Mar 28 2017|Media|

The Hill: FDA critic on Trump’s shortlist to head agency by Sarah Chacko

(This story previously appeared in The Hill Extra) Former biotech executive Joseph Gulfo has been offering the Trump administration advice on how it could reshape the Food and Drug Administration. It seems the administration likes what he has to say. Gulfo, who sparred with the FDA over the approval of a medical device product from 2010 to [...]

Mar 27 2017|Media|

NJ.com: Trump eyeing N.J. college official for FDA job, reports say by Kelly Heyboer

TEANECK -- A Fairleigh Dickinson University official who wrote a book critical of the Food and Drug Administration is one of President Donald Trump's top choices to lead the federal agency, reports say. Joseph Gulfo, executive director of Fairleigh Dickinson's Lewis Center for Healthcare Innovation and Technology, is one of the names being vetted for the FDA commissioner job, according to [...]

Mar 26 2017|Media|

MedPage Today: Who Will Trump Pick to Helm the FDA? by Shannon Firth

WASHINGTON -- President-elect Trump has yet to announce potential candidates to lead the FDA, but several health policy experts shared their picks with MedPage Today. At least two names have been bandied about -- Scott Gottlieb, MD, a resident fellow with the conservative think tank, the American Enterprise Institute, and Jim O'Neill, a libertarian and [...]

Mar 25 2017|Media|

Video: 2017 MedTech Showcase

From 2017 MedTech Showcase. Here is a video of our discussion on raising early stage investments.

Mar 15 2017|Blog|

Weekly Standard: Who Will Lead the FDA? A look at some of the contenders.

Joseph Gulfo, MD: Like Gottlieb, Gulfo is a medical doctor, an important qualification since physicians are frequently the target of restrictive FDA regulations. And like Gottlieb, Gulfo has written extensively in the Wall Street Journal and elsewhere about the FDA, though his prescriptions tend to be more dramatic. For over a decade, the FDA has [...]

Mar 2 2017|Media|

PINKERTON: Trump Lays Down the Law to Big Pharma, Embraces the Cure Strategy via Breitbart

... And it’s not just the number of new approvals that’s a problem, it’s also the nature  of those approvals.  In the words of Joseph V. Gulfo, executive director of the Lewis Center for Healthcare Innovation and Technology at Fairleigh Dickinson University: Cardiovascular disease remains the number cause of death in the United States, yet, [...]

Feb 1 2017|Media|

The Hill: 2016 FDA drug approval numbers — what can Trump conclude?

In 2016, the FDA approved just 22 novel new medicines, a six-year low and half of the 45 approved in 2015. That’s the top line bad news; unfortunately, there is a more disturbing message when one digs a little deeper. Forty-one percent (nine of the 22 drugs) are intended for orphan or rare diseases. Eight [...]

Jan 24 2017|Media|